Generated by AI
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address disease-causing biology without permanently altering DNA. Its current pipeline includes lead candidate KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide under development for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, along with additional research programs in liver and other therapeutic areas. Korro Bio’s platform is built around programmable RNA editing and oligonucleotide-based delivery, positioning the company within the growing field of next-generation genetic medicines. Based in Cambridge, Massachusetts, Korro Bio focuses on discovery and development activities across its research and clinical-stage portfolio.
Website30 Hudson Yards
New York, NY, 10001
United States
The latest articles about KKR.
Parent company House Foods to sell operator in $1bn deal
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of May 8's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about KKR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.